; and (ii) enter into multiyear contracts (each of which shall have a term of no less than 5 years) with private entities to ensure the availability, in the event of a public health emergency, of adequate domestic supplies of each designated critical medication, as determined by the Secretary under section 319F–5, in lieu of or as a supplement to procuring and maintaining in such stockpile or stockpiles a physical accumulation of such designated critical medications, through measures which may include— (I) one or more private entities’ agreement to maintain specified inventory levels, in specified domestic locations, of one or more such designated critical medications, or of one or more key ingredients thereof (including active pharmaceutical ingredients), under specified conditions (including maintenance and inventory replacement prior to expiration), and to make specified quantities of such designated critical medications or key ingredients thereof available when directed by the Secretary, on predetermined terms and conditions; (II) one or more private entities’ agreement to commence or maintain production of one or more such designated critical medications, in specified locations, or to build or maintain specified surge capacity for such production, and to manufacture or otherwise make specified quantities of such designated critical medications available, when directed, on predetermined terms and conditions; and (III) compensation for maintenance of such inventory, production, or production capacity and associated overhead, as necessary or appropriate. (B) Factors In entering into contracts under subparagraph (A)(ii), the Secretary shall take into account as factors more significant than price— (i) whether the designated critical medication would be produced in the United States